The authors concluded that although the initial response to CAR-T therapy is predominantly mediated by the CD8+ and double negative (CD4-CD8-Helioshi) population, at later time points a distinct population of CD4+ CAR-T cells is responsible for cytotoxicity against leukemia cells. This evidence concerns the gene CD8A and leukemia.